01 Preference for Non-Thermal Pulsed Field Ablation The ablation devices market analysis indicates higher adoption of pulsed field ablation for treating cardiac arrhythmias. This technology uses electrical pulses to target abnormal heart tissue while reducing thermal injury risks. Hospitals are increasingly considering PFA systems for their safety and procedural efficiency. For example, Boston Scientific's MANIFEST-17K study involving 17,642 patients reported major adverse event rates below 1%.
02 Integration of Cardiac Mapping and Ablation Systems The integration of cardiac mapping and ablation technologies is becoming an important market trend. Manufacturers are developing systems that combine real-time electrical mapping with precise energy delivery. These integrated platforms help physicians identify abnormal heart signals and improve treatment accuracy.
01 Supply chain disruptions are expected to have a moderate impact on the ablation devices market share due to shortages of medical-grade components, semiconductors, and specialized catheters. The market is expected to experience a K-shaped recovery, as established manufacturers can restore production faster. Smaller manufacturers may face higher procurement costs and delivery delays. The market is projected to grow at a CAGR of 10.15%. Supply chain constraints could reduce short-term growth by approximately 1.5 percentage points, resulting in a growth of 8.65%.
01 The ablation devices market forecasts continued investment in pulsed field ablation technologies, clinical trials, and manufacturing expansion.
02 Key Investment and Funding Activities in Ablation Devices Market, 2025 Company Value (USD) Details Kardium Inc. USD 250 Million In July 2025, Kardium secured funding to support the commercial launch of its Globe Pulsed Field System and expand manufacturing capacity. EnChannel Medical Ltd. USD 82.2 Million In May 2025, EnChannel Medical raised Series B funding to advance its cardiac mapping and pulsed field ablation technologies and support clinical trials.
01 Increasing Atrial Fibrillation Cases and Clinical Evidence Supporting Ablation as First-Line Treatment Drives Market High prevalence of atrial fibrillation is increasing demand for catheter ablation procedures. According to the American Heart Association, approximately 10.55 million U.S. adults have atrial fibrillation, accounting for 4.48% of the adult population in 2026. The need for effective rhythm control is encouraging the adoption of catheter ablation over long-term drug therapy in suitable patients. This supports demand for radiofrequency and cryoablation devices across cardiac treatment centers.Clinical acceptance of catheter ablation as an early treatment option is supporting market growth. European Society of Cardiology guidelines recommend catheter ablation as a first-line rhythm control option for suitable patients with paroxysmal atrial fibrillation. Physician confidence and wider inclusion of ablation in clinical treatment guidelines encourage hospitals to adopt advanced ablation devices.
01 High Capital Investment and Shortage of Skilled Electrophysiologists Restrain Market Expansion Ablation procedures require expensive equipment and specialized clinical infrastructure. Hospitals must invest in ablation generators and compatible catheters. Cardiac procedures may also require advanced mapping systems. These requirements increase the financial burden on smaller healthcare facilities.The limited availability of trained electrophysiologists is restricting the adoption of advanced cardiac ablation devices. Catheter ablation procedures require specialized expertise in cardiac mapping and precise energy delivery. The shortage of qualified professionals limits procedural capacity, particularly in rural hospitals and developing healthcare markets.
01 Development of Non-invasive Histotripsy Technology and Expanding Application in Thyroid Nodule Treatment Creates Growth Opportunities Development of histotripsy technology offers opportunities for noninvasive tumor ablation. This technology uses focused ultrasound waves to destroy targeted tissue without thermal energy. The HOPE4LIVER clinical trial reported 95% technical success in 44 treated tumors. Such findings create opportunities for manufacturers to develop advanced ultrasound-based ablation systems for oncology applications.According to the American Thyroid Association's data, approximately 10–15% of benign thyroid nodules can grow and cause symptoms. The growing interest in nonsurgical treatment options is creating opportunities for specialized ablation devices across endocrinology and outpatient treatment centers.